挽救性苯达莫司汀治疗 T 细胞肿瘤。
Bendamustine salvage therapy for T cell neoplasms.
机构信息
Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, p.le S. Maria Misericordia 15, 33100, Udine, Italy.
出版信息
Ann Hematol. 2013 Sep;92(9):1249-54. doi: 10.1007/s00277-013-1746-9. Epub 2013 Apr 17.
Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.
治疗复发/难治性 T 细胞肿瘤是未满足的医疗需求。我们回顾性记录了 20 例连续的成人 T 细胞肿瘤患者（8 例 T 细胞非特指型淋巴瘤（T-NOS）、4 例血管免疫母细胞性 T 细胞淋巴瘤（AILT）、3 例前体淋巴细胞白血病（T-PLL）、3 例晚期蕈样真菌病（MF）或 Sezary 综合征（SS）和 2 例 T 细胞大颗粒淋巴细胞白血病（T-LGL）），这些患者接受了苯达莫司汀治疗。9 例（45%）和 2 例（10%）患者分别达到部分缓解（PR）和完全缓解（CR），其中 3 例 T-NOS 患者 PR，1 例 AILT 患者 CR，3 例 T-PLL 患者 PR，2 例 MF/SS 患者 PR，1 例 T-LGL 淋巴瘤患者 CR 和 1 例 PR。6 个月的估计无进展生存期和总生存期分别为 44%和 67%。中性粒细胞减少症和血小板减少症的发生率分别为 44%和 25%。4 例患者发生严重感染并发症。在中位随访 6 个月（范围 1-18 个月）时，13 例患者存活，7 例患者死亡，均因淋巴瘤进展所致。苯达莫司汀值得进一步在 T 细胞肿瘤患者中进行研究。
Zotero 插件